Velosulin

Country: European Union

Language: Latvian

Source: EMA (European Medicines Agency)

Active ingredient:

Insulin human

Available from:

Novo Nordisk A/S

ATC code:

A10AB01

INN (International Name):

insulin human (rDNA)

Therapeutic group:

Cukura diabēts

Therapeutic area:

Cukura diabēts

Therapeutic indications:

Cukura diabēta ārstēšana.

Product summary:

Revision: 5

Authorization status:

Atsaukts

Authorization date:

2002-10-07

Patient Information leaflet

                                Zāles vairs nav reğistrētas
22
B. LIETOŠANAS INSTRUKCIJA
Zāles vairs nav reğistrētas
23
LIETOŠANAS INSTRUKCIJA: INFORM CIJA Z
U LIETOT JAM
VELOSULIN 100 SV/ML Š
DUMS INJEKCIJ
M FLAKON
Cilv ka insul ns (_insulinum humanum_), rDNS
PIRMS Z
U LIETOŠANAS UZMAN GI IZLASIET VISU INSTRUKCIJU.
–
Saglab jiet šo instrukciju! Iesp jams, ka v l
k to vajadz s p rlas t.
–
Ja jums rodas v l k di jaut
jumi, vaic jiet
rstam, diab ta apr
pes m sai vai farmaceitam.
–
Š s z les ir parakst tas tieši jums. Nedodiet t
s citiem. T s var nodar t aunumu pat tad, ja šiem
cilv kiem ir l dz gi simptomi.
–
Ja j
s nov rojat jebk das blakuspar
d bas, kas šaj
instrukcij
nav min tas vai k da no min taj
m
blakuspar
d b m jums izpaužas smagi, l
dzu izst
stiet to savam
rstam, diab ta apr
pes m sai vai
farmaceitam.
1.
KAS IR VELOSULIN UN K DAM NOL KAM TO LIETO
VELOSULIN IR CILV KA INSUL NS DIAB TA
RST
ŠANAI. Velosulin ir
tras darb bas insul ns. Tas noz m , ka
Velosulin s ks pazemin t glikozes l meni asin s apm ram p c ½ stundas
p c t
ievad šanas.
2.
PIRMS VELOSULIN LIETOŠANAS
NELIETOJIET VELOSULIN Š DOS GAD JUMOS
_ _
JA JUMS IR ALER IJA (PAAUGSTIN TA JUT BA) pret_ _šo insul nu,
metakrezolu vai k du citu sast
vda u
(skat t _7. S k ka inform cija_).
Aler
ijas simptomus skat t _5. Iesp jam s blakuspar d bas_.
JA J
S SAJ
TAT HIPOGLIK MIJAS tuvošanos (zema glikozes l me a asin s simptomus).
Vair
k par
hipoglik miju skat t _4. K r koties neatliekam situ cij_
.
PAŠA PIESARDZ BA, LIETOJOT VELOSULIN, NEPIECIEŠAMA Š DOS GAD JUMOS
JA JUMS IR nieru vai aknu, virsnieru dziedzera, hipof zes vai
vairogdziedzera DARB BAS TRAUC JUMI.
JA LIETOJAT ALKOHOLU: uzmanieties no hipoglik mijas simptomiem un
nekad nelietojiet alkoholu
tukš d š .
JA JUMS IR LIEL
KA FIZISK SLODZE nek parasti vai j
s v laties main t ierasto di
tu.
SLIMOŠANAS LAIK : nep rtrauciet insul na lietošanu.
JA J
S DODATIES UZ
RVALST M: laika zonu starp ba daž d s valst s ietekm s nepieciešam
bu p c
insul na un ievad šanas laiku.
CITU Z
U LIETOŠANA
Daudzi medikament
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zāles vairs nav reğistrētas
1
PIELIKUMS I
Z
U APRAKSTS
Zāles vairs nav reğistrētas
2
1.
Z
U NOSAUKUMS
Velosulin 100 SV/ml
Š
dums injekcij
m vai inf
zij
m flakon
2.
KVALITAT VAIS UN KVANTITAT VAIS SAST VS
Cilv ka insul ns (_insulinum humanum_), rDNS (ieg ts ar rekombinantas
DNS tehnolo ijas pal dz bu no
_Saccharomyces cerevisiae_).
1 ml satur 100 SV cilv ka insul na.
1 flakon ir 10 ml, kas atbilst 1000 SV
Viena SV (starptautisk vien ba) atbilst 0,035 mg bez dens cilv ka
insul na.
Pilnu pal gvielu sarakstu skat t apakšpunkt
6.1_._
3.
Z
U FORMA
Š
dums injekcij
m vai inf
zij
m flakon .
Dzidrs, bezkr
sains
dens š
dums.
4.
KL NISK INFORM CIJA
4.1
TERAPEITISK S INDIK CIJAS
Cukura diab ta
rst
šana.
4.2
DEVAS UN LIETOŠANAS VEIDS
_ _
Šis fosf
tu-bufer
tais š
stošais insul ns ir paredz ts past
v gai subkut
nai insul na inf
zijai (PSII)
r
jos
insul na inf
zijas s k os.
_ _
Velosulin ir
tras darb bas insul na prepar
ts. To var lietot kop ar noteiktiem ilgstošas darb bas insul na
prepar
tiem. Par nesader bu skat t apakšpunkt
6.2.
DEVAS
Devas ir individu las un
rsts t
s nosaka,
emot v r
pacienta nepieciešam bu p c insul na.
Parasti 40%-60% no kop j
s dienas devas tiek doti k nep rtraukts baz lais komponents un
atlikušie 40%-
60% k _bolus_, sadalot starp tr s galvenaj
m
dienreiz m.
Kopum , kad pacientiem injekcijas nomaina ar inf
zijas terapiju, var b t ieteicams samazin t pacientam
devu uzs kot ar 90% no iepriekš j
s kop j
s dienas devas - ar 40% k baz lo komponentu un 50% k
_bolus_, sadalot starp tr s galvenaj
m
dienreiz m.
Devas ir individu las un tiek noz m tas,
emot v r
pacienta nepieciešam bu p c insul na. Individu l
nepieciešam ba p c insul na parasti ir robež s no 0,3 l dz 1,0 SV/kg
dien . Dien nepieciešamais insul na
daudzums var b t liel
ks pacientiem, kuriem ir rezistence pret insul nu (piem ram, pubert
tes laik vai
aptaukošan s d
), un maz ks pacientiem, kuriem ir saglab jusies endog n insul na
produkcija.
Zāles vairs nav reğistrētas
3
Pacientiem ar cukura diab tu laba vielmai
as kompens c
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-04-2009
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-04-2009
Public Assessment Report Public Assessment Report Bulgarian 15-07-2008
Patient Information leaflet Patient Information leaflet Spanish 17-04-2009
Public Assessment Report Public Assessment Report Spanish 15-07-2008
Patient Information leaflet Patient Information leaflet Czech 17-04-2009
Public Assessment Report Public Assessment Report Czech 15-07-2008
Patient Information leaflet Patient Information leaflet Danish 17-04-2009
Public Assessment Report Public Assessment Report Danish 15-07-2008
Patient Information leaflet Patient Information leaflet German 17-04-2009
Public Assessment Report Public Assessment Report German 15-07-2008
Patient Information leaflet Patient Information leaflet Estonian 17-04-2009
Public Assessment Report Public Assessment Report Estonian 15-07-2008
Patient Information leaflet Patient Information leaflet Greek 17-04-2009
Public Assessment Report Public Assessment Report Greek 15-07-2008
Patient Information leaflet Patient Information leaflet English 17-04-2009
Public Assessment Report Public Assessment Report English 15-07-2008
Patient Information leaflet Patient Information leaflet French 17-04-2009
Public Assessment Report Public Assessment Report French 15-07-2008
Patient Information leaflet Patient Information leaflet Italian 17-04-2009
Public Assessment Report Public Assessment Report Italian 15-07-2008
Patient Information leaflet Patient Information leaflet Lithuanian 17-04-2009
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-04-2009
Public Assessment Report Public Assessment Report Lithuanian 15-07-2008
Patient Information leaflet Patient Information leaflet Hungarian 17-04-2009
Summary of Product characteristics Summary of Product characteristics Hungarian 17-04-2009
Public Assessment Report Public Assessment Report Hungarian 15-07-2008
Patient Information leaflet Patient Information leaflet Maltese 17-04-2009
Public Assessment Report Public Assessment Report Maltese 15-07-2008
Patient Information leaflet Patient Information leaflet Dutch 17-04-2009
Public Assessment Report Public Assessment Report Dutch 15-07-2008
Patient Information leaflet Patient Information leaflet Polish 17-04-2009
Public Assessment Report Public Assessment Report Polish 15-07-2008
Patient Information leaflet Patient Information leaflet Portuguese 17-04-2009
Summary of Product characteristics Summary of Product characteristics Portuguese 17-04-2009
Public Assessment Report Public Assessment Report Portuguese 15-07-2008
Patient Information leaflet Patient Information leaflet Romanian 17-04-2009
Public Assessment Report Public Assessment Report Romanian 15-07-2008
Patient Information leaflet Patient Information leaflet Slovak 17-04-2009
Public Assessment Report Public Assessment Report Slovak 15-07-2008
Patient Information leaflet Patient Information leaflet Slovenian 17-04-2009
Summary of Product characteristics Summary of Product characteristics Slovenian 17-04-2009
Public Assessment Report Public Assessment Report Slovenian 15-07-2008
Patient Information leaflet Patient Information leaflet Finnish 17-04-2009
Public Assessment Report Public Assessment Report Finnish 15-07-2008
Patient Information leaflet Patient Information leaflet Swedish 17-04-2009
Public Assessment Report Public Assessment Report Swedish 15-07-2008

Search alerts related to this product

View documents history